Abraxis BioScience — Merger or Acquisition (June 2010)
25 slides from Abraxis BioScience's merger presentation, Jun 30, 2010
Slide 1: Celgene & Abraxis BioScience Conference Call June 30, 2010
Celgene & Abraxis BioScience Conference Call June 30, 2010
Slide 2: Agenda
STRATEGIC OVERVIEW Sol Barer, PhD, Executive Chairman TRANSACTION OVERVIEW Bob Hugin, CEO ABRAXIS BIOSCIENCE PERSPECTIVE Patrick Soon-Shiong, M.D., Executive Chairman Abraxis BioScience, Inc. CONCLUSION AND Q&A Bob Hugin Agenda
Slide 3: Forward-Looking Statement
Forward-Looking Statement This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under Celgene's control. The Company's actual results, performance, or achievements could be materially different from those projected
Slide 4: Celgene & Abraxis BioScience Rationale
Celgene & Abraxis BioScience Rationale Accelerates Celgene's strategy to become a global leader in hematology and oncology Revenue growth potential in metastatic breast cancer Significant near-term opportunities in NSCLC and pancreatic cancer Leverages innovative nanotechnology platform for life-cyc
Slide 5: Agenda
STRATEGIC OVERVIEW Sol Barer, PhD, Executive Chairman TRANSACTION OVERVIEW Bob Hugin, CEO ABRAXIS BIOSCIENCE PERSPECTIVE Patrick Soon-Shiong, M.D., Executive Chairman Abraxis BioScience, Inc. CONCLUSION AND Q&A Bob Hugin Agenda
Slide 6: Terms of the Agreement
Terms of the Agreement Celgene to acquire all outstanding shares at a value of $72 per share in a combination of cash and common stock ~$2.44B cash ~$565M Celgene stock Abraxis BioScience shareholders will receive Contingent Value Rights for future regulatory milestones and commercial royalties incl
Slide 7: Overview of Abraxis BioScience Inc.
Overview of Abraxis BioScience Inc. Headquarters in Los Angeles, CA Marketing in Bridgewater, NJ Clinical Operations, Regulatory, Medical Affairs in Durham, NC Manufacturing sites in Chicago, Upstate NY; future site Phoenix Lead product ABRAXANE(r) (nab-paclitaxel) Approved in 2005 for metastatic br
Slide 8: Abraxis BioScience Pipeline
Abraxis BioScience Pipeline ABRAXANE(r) Breast (Metastatic) Lung (Advanced) Metastatic Melanoma Pancreatic (Advanced) ABI-008 (nab(r)-docetaxel) Prostate (Hormone Refractory) ABI-009 (nab(r)-rapamycin) ABI-011 (nab(r)-5404) Vascular Disrupting Agent - -Solid Tumors ABI-010 (nab(r)-17AAG) Hsp90 Inhib
Slide 9: ABRAXANE: Lead Compound Utilizing nab Technology
Mean size ~130 nm Leads to increased transport and accumulation of albumin-bound paclitaxel in tumors ABRAXANE(r): Lead Compound Utilizing nab(r) Technology ABRAXANE Value Proposition Improved clinical outcomes in metastatic breast cancer and lung cancer vs. paclitaxel Emerging, unprecedented data i
Slide 10: Approved for Metastatic Breast Cancer
Source: Gradishar, J Clin Oncol 23:7794-7803 Approved for Metastatic Breast Cancer Overall Survival in >2nd Line Patients Approved by U.S. FDA in January 2005 for metastatic breast cancer Approval based on response rate in randomized Phase III: 33% vs 19%, p=0.001 Increased time to tumor progression
Slide 11: ABRAXANE in Metastatic Breast Cancer
ABRAXANE(r) in Metastatic Breast Cancer Source: Tandem Apr 2010, Rolling 12 Mos, Regimens Key Growth Drivers Taxane market leader Re-launch current superior product profile versus solvent- based taxanes Emerging Phase II combination data with targeted, biologic, and chemotherapy agents Ongoing Phase
Slide 12: Advanced NSCLC Market Overview
Advanced NSCLC Market Overview Treatment driven by histology Platinum / Taxane doublets are the leading regimens Advancements in the treatment of patients with non-squamous histology include Avastin and Alimta Squamous histology remains significantly underserved ~70% Non-Squamous ~30% Squamous NSCLC
Slide 13: NSCLC Phase III Registration Trial
Chemo-naive PS 0-1 Stage IIIb/IV NSCLC N = 1,050 ABRAXANE(r) 100 mg/m2 d1, 8 15 Carboplatin AUC 6 d1 21 Day Cycles No Premedication n = 525 1:1 Paclitaxel 200 mg/m2 d1 Carboplatin AUC 6 d1 21 Day Cycles With Premedication of Dexamethasone + Antihistamines n = 525 NSCLC Phase III Registration Trial C
Slide 14: ABRAXANE Key Growth Drivers in NSCLC
ABRAXANE(r) Key Growth Drivers in NSCLC Potential regulatory submission H1 2011 SPA primary endpoint of ORR met Results in NSCLC confirm superiority versus paclitaxel* ORR 33% vs. 25% (31% improvement), p=.005 PFS and OS data expected late 2010 Clinically meaningful increase in ORR for squamous hist
Slide 15: Pancreatic Cancer Overview
Pancreatic Cancer Overview Significant unmet need Currently available therapies offer ~10% response rate and ~6 months survival Current standard of care is gemcitabine +/- erlotinib Pancreatic Cancer U.S. 40k Patients Resectable / Curative Intent Unresectable 1st line U.S. 32k Patients Palliative Ca
Slide 16: ABRAXANE Key Growth Drivers in Pancreatic Cancer
ABRAXANE(r) Key Growth Drivers in Pancreatic Cancer Strong biologic rationale Significant over-expression of SPARC Emerging Phase I/II data in combination with gemcitabine compares favorably vs. historical controls N=67 Overall Response Rate of 46% is ~4x historical controls PET CR Rate of 13% Doubl
Slide 17: PET Scan From Pancreatic Cancer Patient in Phase I/II Study
PET Scan From Pancreatic Cancer Patient in Phase I/II Study Baseline: 02.08.2008 Post Rx 2: 05.01.2008
Slide 18: Pancreatic Cancer Phase III Registration Trial Ongoing
Pancreatic Cancer Phase III Registration Trial Ongoing First-line metastatic pancreatic adenocarcinoma randomization n=630 ABRAXANE(r) 125 mg/m2 iv over 30 min + Gemcitabine 1000 mg/m2 qw 3 of 4 wks No standard premedication 1:1 Gemcitabine 1000 mg/m2 qw 7 of 8 wks qw 3 of 4 wks Rapidly Accruing
Slide 19: Value Proposition
Value Proposition Leverage combined commercial experience to advance market leadership of ABRAXANE(r) in metastatic breast cancer Advance preparations for FDA approval and commercial launch of ABRAXANE in lung cancer Accelerate accrual of Phase III pancreatic cancer registration trial and capitalize
Slide 20: Agenda
STRATEGIC OVERVIEW Sol Barer, PhD, Executive Chairman TRANSACTION OVERVIEW Bob Hugin, CEO ABRAXIS BIOSCIENCE PERSPECTIVE Patrick Soon-Shiong, M.D., Executive Chairman Abraxis BioScience, Inc. CONCLUSION AND Q&A Bob Hugin Agenda
Slide 21: Abraxis BioScience Pipeline
Abraxis BioScience Pipeline ABRAXANE(r) Breast (Metastatic) Lung (Advanced) Metastatic Melanoma Pancreatic (Advanced) ABI-008 (nab(r)-docetaxel) Prostate (Hormone Refractory) ABI-009 (nab(r)-rapamycin) ABI-011 (nab(r)-5404) Vascular Disrupting Agent - -Solid Tumors ABI-010 (nab(r)-17AAG) Hsp90 Inhib
Slide 22: Agenda
STRATEGIC OVERVIEW Sol Barer, PhD, Executive Chairman TRANSACTION OVERVIEW Bob Hugin, CEO ABRAXIS BIOSCIENCE PERSPECTIVE Patrick Soon-Shiong, M.D., Executive Chairman Abraxis BioScience, Inc. CONCLUSION AND Q&A Bob Hugin Agenda
Slide 23: Celgene & Abraxis BioScience
Celgene & Abraxis BioScience Combines talented and dedicated teams advancing Celgene's vision of becoming the global leader in hematology and oncology Compelling ABRAXANE(r) clinical data reported at major medical meetings in NSCLC and pancreatic cancer highlights significant growth opportunity Exte
Slide 24: Questions & Answers
Committed to N improving the lives of patients worldwide® Questions & Answers
Slide 25: Celgene & Abraxis BioScience Conference Call June 30, 2010
Celgene & Abraxis BioScience Conference Call June 30, 2010
Abraxis BioScience — Merger or Acquisition (June 2010) on 6ix